New Experimental Pill Significantly Extends Survival for Pancreatic Cancer Patients
Summary
A new experimental pill named Daraxanrasib significantly extends the survival of late-stage pancreatic cancer patients, nearly doubling their lifespan compared to chemotherapy. The drug targets mutations in the KRAS gene, offering new hope for this deadly cancer.
Key Points
- A new experimental drug, Daraxanrasib, has significantly increased survival times for late-stage pancreatic cancer patients.
- Patients taking Daraxanrasib lived an average of 13.2 months versus 6.7 months for those on chemotherapy alone.
- The drug works by targeting KRAS mutations, a difficult-to-treat driver of pancreatic cancer.
- FDA plans to expedite approval and has allowed expanded access to the drug for eligible patients.
